Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS‐ONE trial
Authors: Meessen Jennifer M.T.A. , Cardinale Daniela , Ciceri Fabio , Sandri Maria Teresa , Civelli Maurizio , Bottazzi Barbara , Cucchi GianFranco , Menatti Elisabetta , Mangiavacchi Maurizio , Condorelli Gianluigi , Barbieri Enrico , Gori Stefania , Colombo Alessandro , Curigliano Giuseppe , Salvatici Michela , Pastori Paolo , Ghisoni Francesco , Bianchi Alessandra , Falci Cristina , Cortesi Pietro , Farolfi Alberto , Monopoli Anna , Milandri Carlo , Bregni Marco , Malossi Alessandra , Nassiacos Daniele , Verusio Claudio , Staszewsky Lidia , Leone Roberto , Novelli Deborah , Balconi Giovanna , Nicolis Enrico B. , Franzosi Maria Grazia , Masson Serge , Garlanda Cecilia , Mantovani Alberto , Cipolla Carlo M. , Latini Roberto ,   ICOS‐ONE Study Investigators
Published: May 2020

AbstractAimsA multicentre trial, ICOS‐ONE, showed increases above the upper limit of normality of cardiac troponin (cTn) in 27% of patients within 12 months after the end of cancer chemotherapy (CT) with anthracyclines, whether cardiac protection with enalapril was started at study entry in all (prevention arm) or only upon first occurrence on supra‐normal cTn (troponin‐triggered arm). The aims of the present post hoc analysis were (i) to assess whether anthracycline‐based treatment could induce cardiotoxicity over 36 month follow‐up and (ii) to describe the time course of three cardiovascular biomarkers (i.e. troponin I cTnI‐Ultra, B‐type natriuretic peptide BNP, and pentraxin 3 PTX3) and of left ventricular (LV) function up to 36 months.Methods and resultsEligible patients were those prescribed first‐in‐life CT, without evidence of cardiovascular disease, normal cTn, LV ejection fraction (EF) >50%, not on renin‐angiotensin aldosterone system antagonists. Patients underwent echocardiography and blood sampling at 24 and 36 months. No differences were observed in biomarker concentration between the two study arms, ‘prevention' vs. ‘troponin‐triggered'. During additional follow‐up 13 more deaths occurred, leading to a total of 23 (9.5%), all due to a non‐cardiovascular cause. No new occurrences of LV‐dysfunction were reported. Two additional patients were admitted to the hospital for cardiovascular causes, both for acute pulmonary embolism. No first onset of raised cTnI‐Ultra was reported in the extended follow‐up. BNP remained within normal range: at 36 months was 23.4 ng/L, higher (N.S.) than at baseline, 17.6 ng/L. PTX3 peaked at 5.2 ng/mL 1 month after CT and returned to baseline values thereafter. cTnI‐Ultra peaked at 26 ng/L 1 month after CT and returned to 3 ng/L until the last measurement at 36 months. All echocardiographic variables remained stable during follow‐up with a median LVEF of 63% and left atrial volume index about 24 mL/m2.ConclusionsFirst‐in‐life CT with median cumulative dose of anthracyclines of 180 mg/m2 does not seem to cause clinically significant cardiac injury, as assessed by circulating biomarkers and echocardiography, in patients aged 51 years (median), without pre‐existing cardiac disease. This may suggest either a 100% efficacy of enalapril (given as preventive or troponin‐triggered) or a reassuringly low absolute cardiovascular risk in this cohort of patients, which may not require intensive cardiologic follow‐up.